Astrazeneca Plc (AZN) 29.29 $AZN
AstraZeneca Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 23, 12:52PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 29.29 (+0.59)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.39% Gain
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 29.29 (+0.59)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), AZN: 29.29 (+0.59), GSK: 42.56 (+0.80)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 83.37 (+0.92), PFE: 34.59 (+0.12), MRK: 57.68 (+0.64), AZN: 29.29 (+0.59)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.34% Loss
Comtex SmarTrend(R) - Tue Jun 14, 1:47PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 29.29 (+0.59)
Look for Shares of AstraZeneca to Potentially Rebound after Yesterday's 1.34% Sell Off
Comtex SmarTrend(R) - Tue Jun 14, 1:45PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 29.29 (+0.59)
AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
BusinessWire - Sat Jun 11, 10:00AM CDT
--When co-administered with a potassium-sparing agent, FARXIGA reduced A1C, body weight and systolic blood pressure without significantly increasing potassium levels
AZN: 29.29 (+0.59)
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
--Additional poster further explores the impact of BYDUREON on 24-hour glucose patterns in patients with type 2 diabetes
AZN: 29.29 (+0.59)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 233.51 (+4.96), IRWD: 12.95 (+0.31), AZN: 29.29 (+0.59), JNP: 7.08 (+0.10)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 22.25 (+0.61), AZN: 29.29 (+0.59), VRX.TO: 28.34 (+0.61)
AstraZeneca Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 2:30PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 29.29 (+0.59)
AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76th Scientific Sessions
BusinessWire - Wed Jun 08, 7:00AM CDT
--21 abstracts on dapagliflozin, including an investigation of its effects on cardiovascular risk factors in type 2 diabetes with varying degrees of renal function and insights on its use in a real-world setting
AZN: 29.29 (+0.59)
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 56.27 (+3.48), AZN: 29.29 (+0.59), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)
Tagrisso (Osimertinib) Shows Clinical Activity in Patients with Leptomeningeal Disease from Lung Cancer
BusinessWire - Mon Jun 06, 11:38AM CDT
--Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
AZN: 29.29 (+0.59)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 56.27 (+3.48), AZN: 29.29 (+0.59), RTRX: 18.49 (+0.01), PBYI: 33.65 (+2.12)
LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
BusinessWire - Sun Jun 05, 10:50AM CDT
AstraZeneca today presented results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial. These results support the previously reported benefits of olaparib in progression-free survival (PFS) compared to placebo, the primary endpoint of the trial.
AZN: 29.29 (+0.59)
Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer
BusinessWire - Sun Jun 05, 9:42AM CDT
--PD-L1 expression correlates with response to durvalumab monotherapy per Ventana SP263 assay(1)
AZN: 29.29 (+0.59)
AstraZeneca Sells Zurampic's EU and Latin American Rights
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:19AM CDT
AstraZeneca (AZN) entered into a licensing agreement granting Gr??nenthal the rights to its gout drug Zurampic in the EU and Latin America.
IRWD: 12.95 (+0.31), ANIP: 56.27 (+3.48), AZN: 29.29 (+0.59), BMY: 72.64 (+0.33)
SeeThruEquity Issues Company Update on TapImmune Highlighting New Phase 2 Clinical Study with AstraZeneca to Begin at Memorial Sloan Kettering
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
AZN: 29.29 (+0.59)
AstraZeneca Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 23, 12:52PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 29.29 (+0.59)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.39% Gain
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 29.29 (+0.59)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), AZN: 29.29 (+0.59), GSK: 42.56 (+0.80)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 83.37 (+0.92), PFE: 34.59 (+0.12), MRK: 57.68 (+0.64), AZN: 29.29 (+0.59)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.34% Loss
Comtex SmarTrend(R) - Tue Jun 14, 1:47PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 29.29 (+0.59)
Look for Shares of AstraZeneca to Potentially Rebound after Yesterday's 1.34% Sell Off
Comtex SmarTrend(R) - Tue Jun 14, 1:45PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 29.29 (+0.59)
AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
BusinessWire - Sat Jun 11, 10:00AM CDT
--When co-administered with a potassium-sparing agent, FARXIGA reduced A1C, body weight and systolic blood pressure without significantly increasing potassium levels
AZN: 29.29 (+0.59)
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
--Additional poster further explores the impact of BYDUREON on 24-hour glucose patterns in patients with type 2 diabetes
AZN: 29.29 (+0.59)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 233.51 (+4.96), IRWD: 12.95 (+0.31), AZN: 29.29 (+0.59), JNP: 7.08 (+0.10)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 22.25 (+0.61), AZN: 29.29 (+0.59), VRX.TO: 28.34 (+0.61)
AstraZeneca Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 2:30PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 29.29 (+0.59)
AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76th Scientific Sessions
BusinessWire - Wed Jun 08, 7:00AM CDT
--21 abstracts on dapagliflozin, including an investigation of its effects on cardiovascular risk factors in type 2 diabetes with varying degrees of renal function and insights on its use in a real-world setting
AZN: 29.29 (+0.59)
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 56.27 (+3.48), AZN: 29.29 (+0.59), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)
Tagrisso (Osimertinib) Shows Clinical Activity in Patients with Leptomeningeal Disease from Lung Cancer
BusinessWire - Mon Jun 06, 11:38AM CDT
--Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
AZN: 29.29 (+0.59)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 56.27 (+3.48), AZN: 29.29 (+0.59), RTRX: 18.49 (+0.01), PBYI: 33.65 (+2.12)
LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
BusinessWire - Sun Jun 05, 10:50AM CDT
AstraZeneca today presented results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial. These results support the previously reported benefits of olaparib in progression-free survival (PFS) compared to placebo, the primary endpoint of the trial.
AZN: 29.29 (+0.59)
Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer
BusinessWire - Sun Jun 05, 9:42AM CDT
--PD-L1 expression correlates with response to durvalumab monotherapy per Ventana SP263 assay(1)
AZN: 29.29 (+0.59)
AstraZeneca Sells Zurampic's EU and Latin American Rights
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:19AM CDT
AstraZeneca (AZN) entered into a licensing agreement granting Gr??nenthal the rights to its gout drug Zurampic in the EU and Latin America.
IRWD: 12.95 (+0.31), ANIP: 56.27 (+3.48), AZN: 29.29 (+0.59), BMY: 72.64 (+0.33)
SeeThruEquity Issues Company Update on TapImmune Highlighting New Phase 2 Clinical Study with AstraZeneca to Begin at Memorial Sloan Kettering
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
AZN: 29.29 (+0.59)
